Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp

Trang T Ly, Marc D Breton, Patrick Keith-Hynes, Daniel De Salvo, Paula Clinton, Kari Benassi, Benton Mize, Daniel Chernavvsky, Jéróme Place, Darrell M Wilson, Boris P Kovatchev, Bruce A Buckingham, Trang T Ly, Marc D Breton, Patrick Keith-Hynes, Daniel De Salvo, Paula Clinton, Kari Benassi, Benton Mize, Daniel Chernavvsky, Jéróme Place, Darrell M Wilson, Boris P Kovatchev, Bruce A Buckingham

Abstract

Objective: To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.

Research design and methods: The Diabetes Assistant (DIAS) USS used the Dexcom G4 Platinum glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.

Results: Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).

Conclusions: The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Figures

Figure 1
Figure 1
DIAS control to range system.
Figure 2
Figure 2
USS. Glycemic risk as a function of glycemia by time of night. Glycemic risk is depicted to be high (red), moderate (amber), or low (green).
Figure 3
Figure 3
Per-protocol analysis of percent time spent in range for OCL nights (n = 41) versus sensor-augmented pump nights (n = 39). Results are mean ± SD. *P < 0.05.
Figure 4
Figure 4
Per-protocol analysis of sensor glucose values over 8 h during OCL (n = 41) versus sensor-augmented pump nights (n = 39). Results are mean ± SD.

References

    1. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:743–751
    1. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934–939
    1. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Tech 2010;4:1374–1381
    1. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:d1855.
    1. O'Grady MJ, Retterath AR, Keenan DB, et al. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35:2182–2187
    1. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36:1851–1858
    1. Breton M, Farret A, Bruttomesso D, et al. International Artificial Pancreas Study Group Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230–2237
    1. Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ., 3rd Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Tech 2010;4:961–975
    1. Cemeroglu AP, Thomas JP, Zande LT, et al. Basal and bolus insulin requirements in children, adolescents and young adults with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII): effect of age and puberty. Endocr Pract 2013;19:805–811
    1. Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008;31:44–46
    1. Hasan KS, Kabbani M. Mini-dose glucagon is effective at diabetes camp. J Pediatr 2004;144:834.
    1. Place J, Robert A, Ben Brahim N, et al. DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Tech 2013;7:1427–1435
    1. Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yellow-green “traffic” lights using continuous glucose monitoring and insulin pump data. J Diabetes Sci Tech 2010;4:1146–1155
    1. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667–E677
    1. Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009;32:240–244
    1. Desalvo DJ, Keith-Hynes P, Peyser T, et al. Remote glucose monitoring in camp setting reduces the risk of prolonged nocturnal hypoglycemia. Diabetes Technol Ther 2014;16:1–7
    1. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824–833
    1. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013;36:838–844
    1. Murphy HR, Kumareswaran K, Elleri D, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011;34:2527–2529

Source: PubMed

3
Suscribir